CPI part of consortium to develop intelligent packaging for pharmaceuticals
Published: 9 November 2015 - Lisa Peake
The Centre for Process Innovation (CPI) is part of a UK based consortium developing technologies that will spearhead the commercialisation of intelligent pharmaceutical packaging
The project titled ‘REMEDIES’, launched in 2014 and due for completion March 2018, is headed by GlaxoSmithKline with research led by the University of Cambridge’s Institute for Manufacturing. It brings together key players in the pharmaceutical supply chain to bring new emerging technologies to market which have the potential to improve medicine manufacturing and supply and offer more personalised, faster and cheaper drug delivery.
CPI’s role is to collaborate with the project partners who include GlaxoSmithKline and AstraZeneca to develop and scale up ‘smart packaging’ concepts incorporating printed electronics. The partners will work together to commercialise product prototypes and create a market ready supply chain that facilitates mass market adoption within the UK.
The integration of printed electronics into packaging opens up a wide range of market opportunities to create added value for the pharmaceutical industry; providing benefits for producers, distributors and consumers alike. Printed electronics within packaging can improve patient outcomes and compliance by providing information and validation around anti-counterfeiting, product tampering and whether the drug is fit for consumption. Smart packaging is also easily integrated with Near Field Communication (NFC), Radio-frequency Identification (RFID) and other wireless based applications providing the opportunity to optimise logistics operations and stock control within the product life cycle.
Commenting on the project, Dr Alan McClleland, Business Manager at CPI said:
“CPI are delighted to be involved in the REMEDIES project. The ability to integrate printed sensors into pharmaceutical packaging opens up a host of opportunities for the industry both in improving patient care and the logistics associated with the product life cycle. Going forward the key is to develop new innovative products and technologies to market volumes and price points that facilitate mass market adoption. The project is bridging that gap and will position the UK as a world leader in the next generation of pharmaceutical products, processes, and business model innovations.”
Source: Micro Matters